Orofacial pain conditions, particularly those involving muscle hyperactivity such as bruxism and temporomandibular disorders, affect millions of individuals worldwide [1]. As researchers and clinicians seek effective treatments, botulinum toxin type A (BoNT-A) has emerged as a popular intervention. However, a critical examination of the research evidence reveals a complex picture that challenges some commonly held assumptions about this treatment’s efficacy.
The Promise and the Reality: What Polysomnographic Data Reveals
The most rigorous examination of BoNT-A for sleep bruxism comes from the 2018 double-blind, placebo-controlled study by Ondo et al., which included polysomnographic measurements, the gold standard for objectively assessing sleep bruxism activity [2]. While this study is often cited as supportive evidence, a closer look at the raw data tells a more nuanced story.
Among the 13 participants in the BoNT-A group, only 2 demonstrated substantial reductions in bruxism events and total bruxing time per hour. The remainder showed either modest improvements, no significant change, or even increased bruxism activity. The study reported that bruxism events in the BoNT-A group improved from 9.18 ± 8.48/h to 6.95 ± 7.04/h, while the placebo group saw events increase from 4.63 ± 3.45/h to 10.65 ± 9.57/h. Despite these seemingly positive results, the p-value for this comparison was 0.09—failing to reach statistical significance.
This disconnect between subjective improvements and objective measurements represents a recurring theme in orofacial pain research. While patients in the Ondo study reported significant symptomatic improvement (p < 0.05 for Clinical Global Impression and Visual Analog Scale scores), the objective bruxism activity measured by polysomnography did not reach statistical significance [2]. This suggests that BoNT-A may be more effective for managing the painful symptoms associated with bruxism than actually reducing the underlying muscle activity itself.
Methodological Challenges in Orofacial Pain Research
Several methodological factors complicate research in this field. The significant night-to-night variation in bruxism severity makes single-night polysomnographic recordings potentially unreliable [2]. As noted by Carra et al., there is no universally accepted protocol for quantifying bruxism episodes in polysomnographic studies, with research showing only moderate diagnostic accuracy when audio-video recordings are absent [4]. Most studies have relatively few subjects, and patients referred to specialty clinics often represent more severe cases, creating potential selection bias [10].
The blinding problem presents another significant challenge. Most studies fail to include blinding validation protocols, a crucial omission given the high expectation effects associated with visible facial changes following BoNT-A injections [2]. When injecting 200 units of botulinum toxin into jaw muscles, patients may easily detect whether they received active treatment, potentially compromising the study’s integrity.
Like what you’re learning? Download a brochure for our Orofacial Pain and Oral Medicine certificate or master’s degree program.
Understanding the Mechanism: Strength vs. Drive
Research by Shim et al. provides important insights into BoNT-A’s actual mechanism of action [5]. Their polysomnographic evaluation found that while BoNT-A reduced voluntary maximum bite force levels, it produced no significant changes in the actual number of bruxism episodes per hour or rhythmic masticatory muscle activity during sleep. This finding supports the hypothesis that BoNT-A primarily affects muscle strength rather than the neurological mechanisms triggering bruxism events.
At clinically acceptable doses (typically well under 3 units per kilogram), BoNT-A does not induce full paralysis or complete muscle inactivity. Patients retain voluntary movement, and objective signs of complete tone suppression are rarely reported. This partial weakening, affecting perhaps the top 20% of maximum voluntary activity, might explain modest symptom improvements rather than true suppression of low-level muscle tone.
Central vs. Peripheral Effects
The question of whether BoNT-A can modulate central neural mechanisms such as long-term potentiation in motor neurons remains largely speculative. While some imaging and electrophysiological studies suggest BoNT-A may induce cortical changes by reducing afferent feedback from muscles [8], the relevance of these findings to stress-induced or psychogenic hypertonicity remains unproven.
Research evidence supports behavioral and central treatments showing greater potential for reducing central excitability than peripheral neurotoxins. Daily stretching, for example, has been demonstrated to inhibit the jaw stretch reflex and induce presynaptic inhibition in trigeminal pathways, effects that may address the underlying neural drive rather than simply weakening the effector muscles [5].
Clinical Implications and Future Directions
For clinicians treating orofacial pain conditions, these research findings carry important implications. As noted in evidence-based reviews by Long et al. and Tinastepe et al., while BoNT-A shows promise for bruxism treatment, the evidence remains limited and requires further investigation with standardized protocols [3, 6]. Studies examining BoNT-A for other orofacial pain conditions, such as myofascial pain, show mixed results, with many relying heavily on subjective measures rather than objective assessments [7].
The research suggests that BoNT-A may offer benefits for orofacial pain patients, particularly for pain management, but the objective evidence for reduction in actual bruxism activity is less convincing than often portrayed. Patients and clinicians should maintain realistic expectations: BoNT-A may help manage the painful consequences of muscle hyperactivity, but evidence for consistently reducing the underlying drive remains limited.
Conclusion
The body of research examining BoNT-A for orofacial pain conditions reveals a treatment that provides modest benefits primarily through muscle weakening rather than addressing central mechanisms. While subjective improvements are commonly reported, objective measurements often fail to reach statistical significance. Future research should focus on standardized protocols, validated blinding procedures, and longer-term objective assessments to better understand BoNT-A’s role in comprehensive orofacial pain management.
Earn an Online Postgraduate Degree in Orofacial Pain and Oral Medicine
Are you interested in a variety of issues focused on orofacial pain, medicine and sleep disorders? Consider enrolling in the Herman Ostrow School of Dentistry of USC’s online, competency-based certificate or master’s program in Orofacial Pain and Oral Medicine.
References
- Manfredini D, Lobbezoo F. Relationship between bruxism and temporomandibular disorders: a systematic review of literature from 1998 to 2008. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(6):e26-e50.
- Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018;90(7):e559-e564.
- Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: an evidence-based review. Int Dent J. 2012;62(1):1-5.
- Carra MC, Huynh N, Lavigne GJ. Diagnostic accuracy of sleep bruxism scoring in absence of audio-video recording: a pilot study. Sleep Breath. 2014;19(1):183-190.
- Shim YJ, Lee MK, Kato T, Park HU, Heo K, Kim ST. Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographic evaluation. J Clin Sleep Med. 2014;10(3):291-298.
- Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio. 2015;33(4):291-298.
- Ahmed S, et al. Effect of Local Anesthetic Versus Botulinum Toxin-A Injections for Myofascial Pain Disorders: A Systematic Review and Meta-Analysis. Clin J Pain. 2019;35(4):353-367.
- Weise D, Weise CM, Naumann M. Central Effects of Botulinum Neurotoxin-Evidence from Human Studies. Toxins (Basel). 2019;11(1):21.
- Spruijt M, et al. The efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a double blinded randomized controlled trial. BJOG. 2024;132(3):297-305.
- Koyano K, Tsukiyama Y, Ichiki R, Kuwata T. Assessment of bruxism in the clinic. J Oral Rehabil. 2008;35(7):495-508.
